PE20240728A1 - Sistemas de represores de casx disenados por ingenieria genetica - Google Patents

Sistemas de represores de casx disenados por ingenieria genetica

Info

Publication number
PE20240728A1
PE20240728A1 PE2024000522A PE2024000522A PE20240728A1 PE 20240728 A1 PE20240728 A1 PE 20240728A1 PE 2024000522 A PE2024000522 A PE 2024000522A PE 2024000522 A PE2024000522 A PE 2024000522A PE 20240728 A1 PE20240728 A1 PE 20240728A1
Authority
PE
Peru
Prior art keywords
casx
genetic engineering
systems designed
repressor systems
repressor
Prior art date
Application number
PE2024000522A
Other languages
English (en)
Spanish (es)
Inventor
Jason Fernandes
Ross White
Sean Higgins
Sarah Denny
Benjamin Oakes
Emeric Jean Marius Charles
Original Assignee
Scribe Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scribe Therapeutics Inc filed Critical Scribe Therapeutics Inc
Publication of PE20240728A1 publication Critical patent/PE20240728A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22—Ribonucleases [RNase]; Deoxyribonucleases [DNase]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/102—Mutagenizing nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90—Stable introduction of foreign DNA into chromosome
    • C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
    • C12N15/907—Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1003—Transferases (2.) transferring one-carbon groups (2.1)
    • C12N9/1007—Methyltransferases (general) (2.1.1.)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/09—Fusion polypeptide containing a localisation/targetting motif containing a nuclear localisation signal
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/80—Fusion polypeptide containing a DNA binding domain, e.g. Lacl or Tet-repressor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPR]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Mycology (AREA)
  • Cell Biology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
PE2024000522A 2021-09-21 2022-09-21 Sistemas de represores de casx disenados por ingenieria genetica PE20240728A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163246543P 2021-09-21 2021-09-21
US202263321517P 2022-03-18 2022-03-18
PCT/US2022/076774 WO2023049742A2 (en) 2021-09-21 2022-09-21 Engineered casx repressor systems

Publications (1)

Publication Number Publication Date
PE20240728A1 true PE20240728A1 (es) 2024-04-15

Family

ID=83902730

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2024000522A PE20240728A1 (es) 2021-09-21 2022-09-21 Sistemas de represores de casx disenados por ingenieria genetica

Country Status (13)

Country Link
US (2) US20240392271A1 (https=)
EP (1) EP4405479A2 (https=)
JP (1) JP2024534523A (https=)
KR (1) KR20240095525A (https=)
AU (1) AU2022349627A1 (https=)
CA (1) CA3231909A1 (https=)
CL (1) CL2024000835A1 (https=)
GB (1) GB2625500B (https=)
IL (1) IL311610A (https=)
MX (1) MX2024003455A (https=)
PE (1) PE20240728A1 (https=)
TW (1) TW202320864A (https=)
WO (1) WO2023049742A2 (https=)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3980533A1 (en) 2019-06-07 2022-04-13 Scribe Therapeutics Inc. Engineered casx systems
KR20230128289A (ko) 2020-12-03 2023-09-04 스크라이브 테라퓨틱스 인크. 조작된 클래스 2 유형 v crispr 시스템
WO2022261149A2 (en) 2021-06-09 2022-12-15 Scribe Therapeutics Inc. Particle delivery systems
GB2625500B (en) 2021-09-21 2026-04-01 Scribe Therapeutics Inc Engineered CasX repressor systems
WO2023069478A1 (en) * 2021-10-20 2023-04-27 University Of Rochester Methods and compositions for rejuvenating cns glial populations by suppression of transcription factors
WO2023173110A1 (en) * 2022-03-11 2023-09-14 Epicrispr Biotechnologies, Inc. Compositions, systems, and methods for treating familial hypercholesterolemia by targeting pcsk9
JP2025521154A (ja) * 2022-05-31 2025-07-08 リジェネロン・ファーマシューティカルズ・インコーポレイテッド Ｃ９ｏｒｆ７２反復伸長疾患のためのｃｒｉｓｐｒ干渉療法
WO2023235818A2 (en) * 2022-06-02 2023-12-07 Scribe Therapeutics Inc. Engineered class 2 type v crispr systems
WO2023235888A2 (en) 2022-06-03 2023-12-07 Scribe Therapeutics Inc. COMPOSITIONS AND METHODS FOR CpG DEPLETION
TW202413643A (zh) 2022-06-07 2024-04-01 美商斯奎柏治療公司 用於靶向pcsk9的組合物及方法
GB2634837A (en) 2022-06-07 2025-04-23 Scribe Therapeutics Inc Compositions and methods for the targeting of PCSK9
WO2023240027A1 (en) 2022-06-07 2023-12-14 Scribe Therapeutics Inc. Particle delivery systems
US20250361525A1 (en) 2022-06-08 2025-11-27 Scribe Therapeutics Inc. Aav vectors for gene editing
US20250387518A1 (en) * 2022-06-23 2025-12-25 Nchroma Bio, Inc. Compositions and methods for epigenetic regulation of b2m expression
IL317874A (en) 2022-06-24 2025-02-01 Tune Therapeutics Inc Compounds, systems and methods for reducing low density lipoproteins through targeted gene suppression
PE20252746A1 (es) 2023-03-29 2025-12-05 Scribe Therapeutics Inc Composiciones y metodos para el direccionamiento a pcsk9
WO2024206565A1 (en) 2023-03-29 2024-10-03 Scribe Therapeutics Inc. Repressor fusion protein systems
WO2024223911A1 (en) * 2023-04-28 2024-10-31 Ziccum Ab Nanoparticle formulations
WO2024229020A2 (en) * 2023-05-01 2024-11-07 Chroma Medicine, Inc. Compositions and methods for epigenetic regulation of pcsk9 expression
WO2025072293A1 (en) * 2023-09-27 2025-04-03 Scribe Therapeutics Inc. Optimized mrnas encoding casx proteins
CN117143257B (zh) * 2023-10-31 2024-02-09 深圳市帝迈生物技术有限公司 Trim28-krab-znf10二元复合物、制备方法及用于前列腺癌筛查的试剂盒
WO2025101979A1 (en) * 2023-11-08 2025-05-15 Nchroma Bio, Inc. Compositions and methods for epigenetic regulation of genes for treatment of non-alcoholic steatohepatitis or metabolic dysfunction-associated steatohepatitis
CN117887718B (zh) * 2024-03-14 2025-02-28 青岛宝迈得生物科技有限公司 一种mettl6基因抑制剂及其应用
CN120966794A (zh) * 2024-05-16 2025-11-18 君福生物科技(广州)有限公司 用于表观遗传编辑的融合蛋白及其应用
CN118931878B (zh) * 2024-10-14 2025-02-07 内蒙古大学 一种基于CRISPR/dCas9的表观遗传基因编辑系统及其应用

Family Cites Families (112)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5208036A (en) 1985-01-07 1993-05-04 Syntex (U.S.A.) Inc. N-(ω, (ω-1)-dialkyloxy)- and N-(ω, (ω-1)-dialkenyloxy)-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
US5143854A (en) 1989-06-07 1992-09-01 Affymax Technologies N.V. Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof
US5279833A (en) 1990-04-04 1994-01-18 Yale University Liposomal transfection of nucleic acids into animal cells
US5264618A (en) 1990-04-19 1993-11-23 Vical, Inc. Cationic lipids for intracellular delivery of biologically active molecules
US5283185A (en) 1991-08-28 1994-02-01 University Of Tennessee Research Corporation Method for delivering nucleic acids into cells
US5412087A (en) 1992-04-24 1995-05-02 Affymax Technologies N.V. Spatially-addressable immobilization of oligonucleotides and other biological polymers on surfaces
EP1179340A3 (en) 1994-09-30 2003-05-07 INEX Pharmaceutical Corp. Compositions for the introduction of polyanionic materials into cells
US5753613A (en) 1994-09-30 1998-05-19 Inex Pharmaceuticals Corporation Compositions for the introduction of polyanionic materials into cells
AU719001B2 (en) 1994-12-29 2000-05-04 Massachusetts Institute Of Technology Chimeric DNA-binding proteins
US5695937A (en) 1995-09-12 1997-12-09 The Johns Hopkins University School Of Medicine Method for serial analysis of gene expression
US7368551B2 (en) 1998-06-25 2008-05-06 The General Hospital Corporation De novo DNA cytosine methyltransferase genes, polypeptides and uses thereof
US6534261B1 (en) 1999-01-12 2003-03-18 Sangamo Biosciences, Inc. Regulation of endogenous gene expression in cells using zinc finger proteins
ATE353361T1 (de) 2000-04-28 2007-02-15 Sangamo Biosciences Inc Gezielten modifikation der chromatinstruktur
US6919204B2 (en) 2000-09-29 2005-07-19 Sangamo Biosciences, Inc. Modulation of gene expression using localization domains
WO2002057293A2 (en) 2001-01-22 2002-07-25 Sangamo Biosciences, Inc. Modified zinc finger binding proteins
WO2003027247A2 (en) 2001-09-24 2003-04-03 Sangamo Biosciences, Inc. Modulation of stem cells using zinc finger proteins
WO2003072788A1 (en) 2002-02-21 2003-09-04 The Wistar Institute Of Anatomy And Biology Methods and compositions for reversibly controlling expression of target genes in cells
EP1678315B1 (en) 2003-09-19 2011-08-03 Sangamo BioSciences, Inc. Engineered zinc finger proteins for regulation of gene expression
US20070192880A1 (en) 2003-10-03 2007-08-16 University Of Rochester Horming response element binding transregulators
JP4764426B2 (ja) 2004-06-07 2011-09-07 プロチバ バイオセラピューティクス インコーポレイティッド カチオン性脂質および使用方法
WO2007086881A2 (en) 2005-02-14 2007-08-02 Sirna Therapeutics, Inc. Cationic lipids and formulated molecular compositions containing them
WO2009086558A1 (en) 2008-01-02 2009-07-09 Tekmira Pharmaceuticals Corporation Improved compositions and methods for the delivery of nucleic acids
CA2721333C (en) 2008-04-15 2020-12-01 Protiva Biotherapeutics, Inc. Novel lipid formulations for nucleic acid delivery
WO2010108126A2 (en) 2009-03-19 2010-09-23 Fate Therapeutics, Inc. Reprogramming compositions and methods of using the same
US20110071208A1 (en) 2009-06-05 2011-03-24 Protiva Biotherapeutics, Inc. Lipid encapsulated dicer-substrate interfering rna
WO2011000107A1 (en) 2009-07-01 2011-01-06 Protiva Biotherapeutics, Inc. Novel lipid formulations for delivery of therapeutic agents to solid tumors
US8450107B1 (en) 2011-11-30 2013-05-28 The Broad Institute Inc. Nucleotide-specific recognition sequences for designer TAL effectors
AU2013266968B2 (en) 2012-05-25 2017-06-29 Emmanuelle CHARPENTIER Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription
US20140186843A1 (en) 2012-12-12 2014-07-03 Massachusetts Institute Of Technology Methods, systems, and apparatus for identifying target sequences for cas enzymes or crispr-cas systems for target sequences and conveying results thereof
US20140271550A1 (en) 2013-03-14 2014-09-18 The Trustees Of The University Of Pennsylvania Constructs and Methods for Delivering Molecules via Viral Vectors with Blunted Innate Immune Responses
WO2014197748A2 (en) 2013-06-05 2014-12-11 Duke University Rna-guided gene editing and gene regulation
CN106459995B (zh) 2013-11-07 2020-02-21 爱迪塔斯医药有限公司 使用统治型gRNA的CRISPR相关方法和组合物
WO2015138870A2 (en) 2014-03-13 2015-09-17 The Trustees Of The University Of Pennsylvania Compositions and methods for targeted epigenetic modification
HUE060907T2 (hu) 2014-06-25 2023-04-28 Acuitas Therapeutics Inc Új lipidek és lipid nanorészecske formulációk nukleinsavak bevitelére
GB201418965D0 (https=) 2014-10-24 2014-12-10 Ospedale San Raffaele And Fond Telethon
JP2018509387A (ja) 2015-01-21 2018-04-05 フェーズアールエックス インコーポレイテッド 細胞に治療および診断剤を送達するための方法、組成物、ならびにシステム
US11674144B2 (en) 2015-04-16 2023-06-13 California Institute Of Technology Fractional regulation of transcription
TWI906646B (zh) 2015-06-18 2025-12-01 美商博得學院股份有限公司 降低脫靶效應的ｃｒｉｓｐｒ酶突變
PT3313829T (pt) 2015-06-29 2024-07-08 Acuitas Therapeutics Inc Formulações de lípidos e de nanopartículas lipídicas para a administração de ácidos nucleicos
WO2017068077A1 (en) 2015-10-20 2017-04-27 Institut National De La Sante Et De La Recherche Medicale (Inserm) Methods and products for genetic engineering
HRP20230209T1 (hr) 2015-10-28 2023-04-14 Acuitas Therapeutics Inc. Novi lipidi i lipidne formulacije nanočestica za isporuku nukleinskih kiselina
WO2017083722A1 (en) 2015-11-11 2017-05-18 Greenberg Kenneth P Crispr compositions and methods of using the same for gene therapy
US20190127713A1 (en) 2016-04-13 2019-05-02 Duke University Crispr/cas9-based repressors for silencing gene targets in vivo and methods of use
WO2017212007A1 (en) 2016-06-09 2017-12-14 Curevac Ag Cationic carriers for nucleic acid delivery
EP3468612A1 (en) 2016-06-09 2019-04-17 CureVac AG Hybrid carriers for nucleic acid cargo
AU2017280353B2 (en) 2016-06-24 2021-11-11 Inscripta, Inc. Methods for generating barcoded combinatorial libraries
CA3034369A1 (en) 2016-08-19 2018-02-22 Whitehead Institute For Biomedical Research Methods of editing dna methylation
US20190255106A1 (en) 2016-09-07 2019-08-22 Flagship Pioneering Inc. Methods and compositions for modulating gene expression
MX2019003674A (es) 2016-09-30 2021-01-08 Univ California Enzimas modificadoras de ácido nucleico guiadas por arn y métodos de uso de estas.
US20200149039A1 (en) 2016-12-12 2020-05-14 Whitehead Institute For Biomedical Research Regulation of transcription through ctcf loop anchors
WO2018147343A1 (en) 2017-02-07 2018-08-16 Edigene Corporation Method of treating diseases associated with elevated kras expression using crispr-gndm system
WO2018195555A1 (en) 2017-04-21 2018-10-25 The Board Of Trustees Of The Leland Stanford Junior University Crispr/cas 9-mediated integration of polynucleotides by sequential homologous recombination of aav donor vectors
US20230340471A1 (en) 2017-04-23 2023-10-26 Ospedale San Raffaele S.R.L. Permanent Epigenetic Gene Silencing
US11439692B2 (en) 2017-05-17 2022-09-13 Modalis Therapeutics Corporation Method of treating diseases associated with MYD88 pathways using CRISPR-GNDM system
US11072782B2 (en) 2017-07-24 2021-07-27 Albert-Ludwigs-Universitaet Freiburg Construct for epigenetic modification and its use in the silencing of genes
US20190233805A1 (en) 2017-10-04 2019-08-01 The Regents Of The University Of California Targetable proteins for epigenetic modification and methods for use thereof
US11629342B2 (en) 2017-10-17 2023-04-18 President And Fellows Of Harvard College Cas9-based transcription modulation systems
WO2019084140A1 (en) 2017-10-24 2019-05-02 Sangamo Therapeutics, Inc. METHODS AND COMPOSITIONS FOR THE TREATMENT OF RARE DISEASES
US20210047653A1 (en) 2018-01-30 2021-02-18 The University Of Memphis Research Foundation Compositions and methods for regulating a biological process
KR102922694B1 (ko) 2018-04-19 2026-02-03 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 유전자 편집을 위한 조성물 및 방법
US20210284981A1 (en) 2018-07-24 2021-09-16 The Regents Of The University Of California Rna-guided nucleic acid modifying enzymes and methods of use thereof
US12275964B2 (en) 2018-08-22 2025-04-15 The Regents Of The University Of California Variant type V CRISPR/Cas effector polypeptides and methods of use thereof
JP2021534205A (ja) 2018-08-24 2021-12-09 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー ポリヌクレオチドの空間的構成のためのシステムおよび方法
EP3861130A4 (en) 2018-10-02 2022-08-03 Sangamo Therapeutics, Inc. GENETIC MODULATORS
TW202521561A (zh) 2019-04-23 2025-06-01 美商聖加莫治療股份有限公司 染色體9開放讀框72基因表現之調節子及其用途
JP7663513B2 (ja) 2019-05-16 2025-04-16 トラスティーズ オブ ボストン ユニバーシティ 調節された合成遺伝子発現システム
MX2021014478A (es) 2019-05-28 2022-01-06 Astellas Pharma Inc Metodo para tratar distrofia muscular por direccionamiento del gen dmpk.
WO2020247883A2 (en) 2019-06-07 2020-12-10 Scribe Therapeutics Inc. Deep mutational evolution of biomolecules
EP3980533A1 (en) 2019-06-07 2022-04-13 Scribe Therapeutics Inc. Engineered casx systems
EP4010004A4 (en) 2019-08-07 2023-09-13 Altius Institute For Biomedical Sciences Compositions and methods for modulation of gene expression
CA3154759A1 (en) 2019-09-23 2021-04-01 Flagship Pioneering Innovations V, Inc. Modulating genomic complexes
US20220343485A1 (en) 2019-10-02 2022-10-27 Nippon Telegraph And Telephone Corporation Video quality estimation apparatus, video quality estimation method and program
US20230036273A1 (en) 2019-11-27 2023-02-02 The General Hospital Corporation System and method for activating gene expression
EP4069716A1 (en) * 2019-12-06 2022-10-12 Scribe Therapeutics Inc. Particle delivery systems
EP4081533A4 (en) 2019-12-23 2024-03-20 The Regents of The University of California CRISPR-CAS EFFECTOR POLYPEPTIDES AND METHODS OF USE
US20240401032A1 (en) 2020-05-04 2024-12-05 The Board Of Trustees Of The Leland Stanford Junior University Compositions, systems, and methods for the generation, identification, and characterization of effector domains for activating and silencing gene expression
AU2021283185A1 (en) 2020-06-02 2023-01-05 The Regents Of The University Of California Compositions and methods for gene editing
CA3189185A1 (en) 2020-08-14 2022-02-17 Mikko Taipale Krab fusion repressors and methods and compositions for repressing gene expression
CA3192654A1 (en) 2020-09-01 2022-03-10 The Board Of Trustees Of The Leland Stanford Junior Unversity Synthetic miniature crispr-cas (casmini) system for eukaryotic genome engineering
US20240209396A1 (en) 2020-09-01 2024-06-27 Huigene Therapeutics Co., Ltd. Small cas proteins and uses thereof
WO2022104159A1 (en) 2020-11-13 2022-05-19 Duke University Targeted gene regulation of human immune cells with crispr-cas systems
WO2022114243A1 (en) 2020-11-25 2022-06-02 Astellas Pharma Inc. Method for treating muscular dystrophy by targeting dmpk gene
WO2022119957A1 (en) 2020-12-02 2022-06-09 The Regents Of The University Of California Crispr-cas effector polypeptides and methods of use thereof
KR20230128289A (ko) 2020-12-03 2023-09-04 스크라이브 테라퓨틱스 인크. 조작된 클래스 2 유형 v crispr 시스템
WO2022125843A1 (en) 2020-12-09 2022-06-16 Scribe Therapeutics Inc. Aav vectors for gene editing
KR20240011120A (ko) 2020-12-22 2024-01-25 크로마 메디슨, 인크. 후성유전학적 편집을 위한 조성물 및 방법
CA3207166A1 (en) 2021-02-01 2022-08-04 Angelo Leone Lombardo Gene silencing
WO2022261149A2 (en) 2021-06-09 2022-12-15 Scribe Therapeutics Inc. Particle delivery systems
IL310116A (en) 2021-07-20 2024-03-01 Epicrispr Biotechnologies Inc Systems and methods for regulating target genes
WO2023023553A2 (en) 2021-08-17 2023-02-23 The Board Of Trustees Of The Leland Stanford Junior University Compositions, systems, and methods for activating and silencing gene expression
JP2024535672A (ja) 2021-09-08 2024-10-02 メタゲノミ，インク． クラスｉｉ、ｖ型ｃｒｉｓｐｒ系
GB2625500B (en) 2021-09-21 2026-04-01 Scribe Therapeutics Inc Engineered CasX repressor systems
EP4405490A2 (en) 2021-09-23 2024-07-31 Scribe Therapeutics Inc. Self-inactivating vectors for gene editing
WO2023055893A1 (en) 2021-09-30 2023-04-06 Peter Biotherapeutics, Inc. Gene regulation
WO2023093862A1 (en) 2021-11-26 2023-06-01 Epigenic Therapeutics Inc. Method of modulating pcsk9 and uses thereof
CN116497002A (zh) 2022-01-19 2023-07-28 中国科学院动物研究所 工程化的CasX核酸酶、效应蛋白及其用途
JP2025507990A (ja) 2022-03-04 2025-03-21 エピジェニック・セラピューティクス・インコーポレイテッド ゲノム編集の組成物及び方法
WO2023173110A1 (en) 2022-03-11 2023-09-14 Epicrispr Biotechnologies, Inc. Compositions, systems, and methods for treating familial hypercholesterolemia by targeting pcsk9
WO2023178280A2 (en) 2022-03-17 2023-09-21 The Board Of Trustees Of The Leland Stanford Junior University Compositions and methods for modulating alpha-synuclein expression
IL316722A (en) 2022-05-01 2024-12-01 Chroma Medicine Inc Compositions and methods for epigenetic regulation of PCSK9 expression
WO2023235818A2 (en) 2022-06-02 2023-12-07 Scribe Therapeutics Inc. Engineered class 2 type v crispr systems
GB2634837A (en) 2022-06-07 2025-04-23 Scribe Therapeutics Inc Compositions and methods for the targeting of PCSK9
CN114921439B (zh) 2022-06-16 2024-04-26 尧唐(上海)生物科技有限公司 CRISPR-Cas效应子蛋白、其基因编辑系统及应用
WO2023250148A1 (en) 2022-06-23 2023-12-28 Chroma Medicine, Inc. Compositions and methods for epigenetic editing
IL317701A (en) 2022-06-23 2025-02-01 Chroma Medicine Inc Epigenetic editing compositions and methods
IL317874A (en) 2022-06-24 2025-02-01 Tune Therapeutics Inc Compounds, systems and methods for reducing low density lipoproteins through targeted gene suppression
CA3260110A1 (en) 2022-06-24 2023-12-28 European Molecular Biology Laboratory MODULAR TOOL BASED ON CRISPR FOR THE SPECIFIC INTRODUCTION OF EPIGENETIC MODIFICATIONS ON TARGET LOCI
CN119698469A (zh) 2022-08-11 2025-03-25 益杰立科(上海)生物科技有限公司 一种表观编辑靶点的方法及用途
KR20250128349A (ko) 2022-12-23 2025-08-27 에피제닉 테라퓨틱스 피티이 리미티드 융합체 및 이의 용도
PE20252746A1 (es) 2023-03-29 2025-12-05 Scribe Therapeutics Inc Composiciones y metodos para el direccionamiento a pcsk9
WO2024206620A1 (en) 2023-03-29 2024-10-03 Scribe Therapeutics Inc. Messenger rna encoding casx
WO2024206565A1 (en) 2023-03-29 2024-10-03 Scribe Therapeutics Inc. Repressor fusion protein systems

Also Published As

Publication number Publication date
JP2024534523A (ja) 2024-09-20
US20240254466A1 (en) 2024-08-01
AU2022349627A1 (en) 2024-03-21
GB2625500B (en) 2026-04-01
GB2625500A (en) 2024-06-19
IL311610A (en) 2024-05-01
CL2024000835A1 (es) 2024-10-04
US12553037B2 (en) 2026-02-17
GB202405484D0 (en) 2024-06-05
TW202320864A (zh) 2023-06-01
MX2024003455A (es) 2024-04-03
CA3231909A1 (en) 2023-03-30
US20240392271A1 (en) 2024-11-28
KR20240095525A (ko) 2024-06-25
WO2023049742A2 (en) 2023-03-30
WO2023049742A3 (en) 2023-05-04
EP4405479A2 (en) 2024-07-31

Similar Documents

Publication Publication Date Title
PE20240728A1 (es) Sistemas de represores de casx disenados por ingenieria genetica
MX2022001849A (es) Nucleasas guiadas por acido ribonucleico (arn) y sus fragmentos activos y variantes y metodos de uso.
BR112021012665A2 (pt) Polipeptídeos úteis para edição de genes e métodos de uso
DE602006011574D1 (de) Leitsequenzen zur anleitung von polypeptidsekretion und verfahren zur herstellung
BR112020024863A2 (pt) Nucleases guiadas por rna, fragmentos ativos e variantes das mesmas e métodos de uso
MX2020004149A (es) Variantes de desoxirribonucleasa (dnasa).
MX2021010559A (es) Polipéptidos efectores de crispr-cas y métodos de uso de estos.
BR112022021459A2 (pt) Nucleases guiadas por rna, fragmentos ativos e variantes das mesmas e métodos de uso
MX2020013977A (es) Proteínas quiméricas transmembrana y usos de las mismas.
MX2019003674A (es) Enzimas modificadoras de ácido nucleico guiadas por arn y métodos de uso de estas.
MX391337B (es) Sistemas de replicón de arterivirus recombinantes y usos de estos.
BR102016018569A2 (pt) sistemas e métodos de retentor para eletrodo de soldagem com bastão
UY34227A (es) Acido nucleico recombinante que codifica el gen de la toxina axmi270, vectores, células, plantas y sus métodos de empleo
MX2017003847A (es) Proteinas biespecificas activables por proteasas.
BR112022007375A2 (pt) Sequenciamento de tecido intacto em escala clínica e industrial
AR070693A1 (es) Plantas que tienen rasgos aumentados relacionados con el rendimiento y un metodo para obtenerlas a partir de la expresion del polipeptido de nitrato 2 (nrt2)
GT200800154A (es) N-sulfonilacion selectiva de alcoholes 2-amino trifluoroalquilo sustituidos
EA202190454A1 (ru) Новый crispr-ассоциированный белок и его применение
PE20171652A1 (es) Nuevas proteinas especificas para pioverdina y pioquelina
AR109451A1 (es) Composiciones y métodos para preparar anticuerpos basados en el uso de loci mejoradores de expresión
ATE484591T1 (de) Minimale dna sequenz, die als chromatin-isolator wirkt, und deren verwendung für die protein- expression
AR103672A1 (es) Proteína resistente a los herbicidas, gen codificador y su uso
BR112023003526A2 (pt) Proteínas de fusão de coronavírus imunogênicos e métodos relacionados
ECSP17075380A (es) Fusiones de variante iii del receptor de factor de crecimiento epidérmico-mesotelina y métodos para usar los mismos
EP1841871A4 (en) Novel l-lysine-inducible promoter